Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: David Wolfson who wrote (1091)	10/30/1998 3:40:00 PM
From: Harold Lehman	Read Replies (1) \| Respond to of 1501

Dave, from what I understood there were some common intermediates earlier in the synthetic pathway, so I do not believe they were starting completely from scratch. But even at eight steps it's still difficult for two reasons: 1) the sterol nucleus is difficult to synthesize (I don't know why), and 2) it has a unique side chain. This is an unusual, very novel compound. We'll probably be able to track the progress in making this analogue by watching the stock activity and price over the next few weeks or month. I really don't think Salari has any legal claim to any of these compounds. I spoke with people in the Intellecual Property Office at University of Alberta a few months ago, and they told me that Inflazyme has all the patents pertaining to this class of compounds under license. Harold